Layoffs accelerating...

[Anonymous]

it is sad to see this happening.

Why not have LRL go back to basis and rekindle some token natural products research?

With those billions of dollars invested in facilities and equipment, we'll get a couple pennies on the dollar, maximum, for scrap/surplus real estate. This is just plain goofy. All this talk about innovation. What innovation? Making enemies faster than you make new leads?

 

[Anonymous]

it is sad to see this happening.

Why not have LRL go back to basis and rekindle some token natural products research?

With those billions of dollars invested in facilities and equipment, we'll get a couple pennies on the dollar, maximum, for scrap/surplus real estate. This is just plain goofy. All this talk about innovation. What innovation? Making enemies faster than you make new leads?

Years ago (soon after Year X), Lilly sold their natural products sample collection to Albany Molecular Research (AMRI). IN last few years I have seen announcements of several deals between AMRI and other companies involving AMRI's natural product collection (Which I assume is still largely based on the samples they obtained from Lilly). It reminds me of Lilly's equally foolish decisions to get out of the deals with Agouron on the HIV drug that went on to be a blockbuster success and the Vertex Hepatitis C drug which is on the verge of approval and likely blockbuster sales. Lilly R&D portfolio management is and for a long time has appeared quite clueless.

 

[Anonymous]

Years ago (soon after Year X), Lilly sold their natural products sample collection to Albany Molecular Research (AMRI). IN last few years I have seen announcements of several deals between AMRI and other companies involving AMRI's natural product collection (Which I assume is still largely based on the samples they obtained from Lilly). It reminds me of Lilly's equally foolish decisions to get out of the deals with Agouron on the HIV drug that went on to be a blockbuster success and the Vertex Hepatitis C drug which is on the verge of approval and likely blockbuster sales. Lilly R&D portfolio management is and for a long time has appeared quite clueless.

Not to mention the recent sales of the Tippecanoe facility to Evonik, and the Toxicology facility to Covance ($50M) -- plain and simple short-sighted foolishness. Eli Lilly is without doubt gritting his teeth. It's like selling your internal organs to pay the mortgage...